EMPLOYMENT AGREEMENTEmployment Agreement • July 28th, 2022 • Cure Pharmaceutical Holding Corp. • Pharmaceutical preparations • California
This Employment Agreement (this “Agreement”), effective as of July 22, 2022 (the “Effective Date”), is made by and between Cure Pharmaceutical Holding Corp., a Delaware corporation (together with its affiliates and any successor thereto, the “Company”), and Joel Bennett (the “Executive”) (collectively referred to herein as the “Parties”).
July 22, 2022Cure Pharmaceutical Holding Corp. • July 28th, 2022 • Pharmaceutical preparations
This letter confirms the agreement (this “Agreement”), entered into as of July 22, 2022, by and between CURE Pharmaceutical Holding Corp., a Delaware corporation (“Parent”) and TF Tech Ventures, Inc., a Delaware corporation (“Buyer”), in consideration of Buyer’s purchase of certain assets of CURE Pharmaceutical Corporation, a California corporation and wholly-owned subsidiary of Parent (“Seller”) pursuant to that certain Asset Purchase Agreement, dated as of the date hereof, by and between Buyer and Seller (the “APA”). Capitalized terms used herein but not defined herein will have the meaning ascribed thereto in the APA.
PARENT GUARANTYParent Guaranty • July 28th, 2022 • Cure Pharmaceutical Holding Corp. • Pharmaceutical preparations
THIS GUARANTY (“Guaranty”), effective as of July 22, 2022, is made by CURE Pharmaceutical Holding Corp., a Delaware corporation (“Guarantor”), to and for the benefit of TF Tech Ventures, Inc., a Delaware corporation (“Buyer”) and other Buyer Indemnitees (together with Buyer, “Beneficiaries”, and each of them, a “Beneficiary”) (each of Guarantor and Beneficiaries, a “Party” and collectively, the “Parties”). Capitalized terms not otherwise defined herein shall have the meaning given such terms in the Purchase Agreement (as such term is defined below).
TRANSITION SERVICES AGREEMENTTransition Services Agreement • July 28th, 2022 • Cure Pharmaceutical Holding Corp. • Pharmaceutical preparations
This TRANSITION SERVICES AGREEMENT (this “Agreement”) is made this 22nd day of July, 2022, by and between CURE Pharmaceutical Corporation, a California corporation (“Seller”) and TF Tech Ventures, Inc., a Delaware corporation (“Buyer”).
TRADEMARK LICENSE AGREEMENTTrademark License Agreement • July 28th, 2022 • Cure Pharmaceutical Holding Corp. • Pharmaceutical preparations
This Trademark License Agreement (“Agreement”) is made and entered into as of July 22, 2022 (the “Effective Date”) by and between TF Tech Ventures, Inc., a Delaware corporation (“Buyer” or “Licensor”) and CURE Pharmaceutical Corporation, a California corporation (“Seller”), and CURE Pharmaceutical Holding Corp., a Delaware corporation (“Parent”, together with Seller, “Licensees”, and each a “Licensee”) (Licensor and Licensees each a “Party” and collectively, the “Parties”). Capitalized terms not defined in this Agreement will have the meaning specified in the Purchase Agreement (defined below).
ASSET PURCHASE AGREEMENT between CURE Pharmaceutical Corporation, and TF Tech Ventures, Inc. dated as of July 22, 2022Asset Purchase Agreement • July 28th, 2022 • Cure Pharmaceutical Holding Corp. • Pharmaceutical preparations • California
This Asset Purchase Agreement (this “Agreement”), dated as of July 22, 2022, is entered into between CURE Pharmaceutical Corporation, a California corporation (“Seller”), and TF Tech Ventures, Inc., a Delaware corporation (“Buyer”).
